BHVN
Price:
$35.75
Market Cap:
$3.62B
Biohaven Pharmaceutical Holding Company Ltd., a biopharmaceutical company, develops products candidates targeting neurological and neuropsychiatric diseases, and rare disorders in the United States. It offers NURTEC ODT (rimegepant) for the acute treatment of migraine, as well as developing Rimegepant for preventive treatment of migraine; Zavegepant that is in phase III clinical trials for acute and preventive treatment of migraine, as well as respiratory complications and non-migraine studies; and BHV-3100 for non-migraine indications. The company also offers Troriluzole for spinocerebellar ataxia and obsessive compulsive disorders, as well as Alzheimer diseases; BHV-0223, a product for amy...[Read more]
Industry
Biotechnology
IPO Date
2022-09-23
Stock Exchange
NYSE
Ticker
BHVN
According to Biohaven Pharmaceutical Holding Company Ltd.’s latest financial reports and current stock price. The company's current PE Ratio is -3.82. This represents a change of -29.27% compared to the average of -5.40 of the last 4 quarters.
The mean historical PE Ratio of Biohaven Pharmaceutical Holding Company Ltd. over the last ten years is -1.81. The current -3.82 PE Ratio has changed 21.04% with respect to the historical average. Over the past ten years (40 quarters), BHVN's PE Ratio was at its highest in in the December 2017 quarter at 0.66. The PE Ratio was at its lowest in in the December 2019 quarter at -592.87.
Average
-1.81
Median
-1.09
Minimum
-7.47
Maximum
0
Discovering the peaks and valleys of Biohaven Pharmaceutical Holding Company Ltd. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 0%
Maximum Annual PE Ratio = 0
Minimum Annual Increase = 0%
Minimum Annual PE Ratio = -7.47
Year | PE Ratio | Change |
---|---|---|
2023 | -7.47 | 585.61% |
2022 | -1.09 | -10.97% |
2021 | -1.22 | -44.49% |
2020 | -2.20 | 229.21% |
2019 | -0.67 | -Infinity% |
2018 | 0 | 0% |
The current PE Ratio of Biohaven Pharmaceutical Holding Company Ltd. (BHVN) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
-3.26
5-year avg
-2.53
10-year avg
-1.81
Biohaven Pharmaceutical Holding Company Ltd.’s PE Ratio is less than Immunome, Inc. (-2.17), less than Inhibrx Biosciences, Inc. (0.14), less than AgeX Therapeutics, Inc. (-1.48), greater than Icosavax, Inc. (-15.78), greater than Day One Biopharmaceuticals, Inc. (-14.52), greater than Terns Pharmaceuticals, Inc. (-5.12), greater than X4 Pharmaceuticals, Inc. (-6.95), less than Inozyme Pharma, Inc. (-1.92), greater than Mereo BioPharma Group plc (-13.89), greater than Apellis Pharmaceuticals, Inc. (-16.51), greater than Blueprint Medicines Corporation (-44.77), greater than Cerevel Therapeutics Holdings, Inc. (-17.73), greater than Mirati Therapeutics, Inc. (-11.26), less than Amylyx Pharmaceuticals, Inc. (-1.05), greater than Kymera Therapeutics, Inc. (-18.55), greater than Revolution Medicines, Inc. (-13.06), less than C4 Therapeutics, Inc. (-2.55), less than Agios Pharmaceuticals, Inc. (2.89), greater than Nurix Therapeutics, Inc. (-8.05),
Company | PE Ratio | Market cap |
---|---|---|
-2.17 | $687.83M | |
0.14 | $209.76M | |
-1.48 | $27.76M | |
-15.78 | $769.04M | |
-14.52 | $1.28B | |
-5.12 | $492.65M | |
-6.95 | $98.92M | |
-1.92 | $188.22M | |
-13.89 | $589.54M | |
-16.51 | $4.14B | |
-44.77 | $5.75B | |
-17.73 | $8.19B | |
-11.26 | $4.12B | |
-1.05 | $274.19M | |
-18.55 | $2.64B | |
-13.06 | $8.09B | |
-2.55 | $273.18M | |
2.89 | $1.95B | |
-8.05 | $1.39B |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Biohaven Pharmaceutical Holding Company Ltd. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Biohaven Pharmaceutical Holding Company Ltd. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is Biohaven Pharmaceutical Holding Company Ltd.'s PE Ratio?
How is the PE Ratio calculated for Biohaven Pharmaceutical Holding Company Ltd. (BHVN)?
What is the highest PE Ratio for Biohaven Pharmaceutical Holding Company Ltd. (BHVN)?
What is the 3-year average PE Ratio for Biohaven Pharmaceutical Holding Company Ltd. (BHVN)?
What is the 5-year average PE Ratio for Biohaven Pharmaceutical Holding Company Ltd. (BHVN)?
How does the current PE Ratio for Biohaven Pharmaceutical Holding Company Ltd. (BHVN) compare to its historical average?